AACR Names New Editor-in-Chief of the Journal Cancer Prevention Research
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Nickolas Papadopoulos, PhD, as editor-in-chief...
PHILADELPHIA – The American Association for Cancer Research (AACR) today announced the appointment of Nickolas Papadopoulos, PhD, as editor-in-chief...
PHILADELPHIA – Engaging in administrative tasks to estimate costs or pay for care among a cohort of cancer patients...
PHILADELPHIA – The American Association for Cancer Research (AACR) will award Gordon J. Freeman, PhD, FAACR, with the 2024...
Researchers applied single-nucleus RNA sequencing and spatial transcriptomics to identify potential therapeutic targets in brain metastases ORLANDO, Fla. –...
Patients were matched to therapies targeting specific mutations found in their cancers PHILADELPHIA – Genomic sequencing of tumors from...
SAN DIEGO – A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody...
PHILADELPHIA – A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood...
Second-generation PRMT5 inhibitor targets synthetic lethality in several cancer types with MTAP loss BOSTON – AMG 193, a second-generation...
The therapy uses a different mechanism than approved KRAS G12C inhibitors and targets multiple RAS mutations beyond KRAS G12C...
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) released the 14th edition of its annual Cancer Progress...
PHILADELPHIA – Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients...
PHILADELPHIA – First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic...
Patients treated with the durvalumab-based regimen before and after surgery in the AEGEAN trial had a 32% reduction in...
SAN ANTONIO – Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy...
SAN ANTONIO – Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage...
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
Lisa M. Coussens, PhD, FAACR, inaugurated as President PHILADELPHIA — The American Association for Cancer Research (AACR) welcomes Lisa...
Five new members elected to the Board of Directors PHILADELPHIA — The members of the American Association for Cancer...
Outcomes were similar between Black patients and patients of other races PHILADELPHIA – Treatment outcomes were similar between Black...
sFRP2, but not VEGF, may promote angiogenesis in older patients with melanoma PHILADELPHIA – Younger patients with resected melanoma...
PHILADELPHIA: – In patients with soft tissue sarcoma, the concomitant use of gastric acid suppressant (GAS) therapy and the...
SAN ANTONIO – Early circulating tumor cell dynamics were associated with overall survival in patients with metastatic breast cancer,...
SAN ANTONIO – Even with equivalent treatments in women with hormone receptor-positive, HER2-negative breast cancer, black women had significantly...
PHILADELPHIA — Commercial gene expression tests that guide treatment decisions for prostate cancer may not accurately predict risk of...
NEW ORLEANS – Preliminary data from an artificial intelligence model could potentially predict side effects resulting from new combination...
PHILADELPHIA – Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better...
SAN FRANCISCO – Most LGBTQI+ Latinx have been afraid to share their gender identity and/or sexual orientation with a...
PHILADELPHIA — The American Association for Cancer Research (AACR) is recognizing Jedd D. Wolchok, MD, PhD, with the 2020...
PHILADELPHIA — The American Association for Cancer Research (AACR) is proud to announce its newest class of grant recipients. Since 1993,...
“ATLANTA – Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid...